Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04619316
Title Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors University Hospital, Essen
Indications

thyroid gland carcinoma

Therapies

Dabrafenib + Trametinib

Trametinib

Age Groups: adult | senior
Covered Countries DEU

Additional content available in CKB BOOST